Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark Pharma enters into an Exclusive Licensing Agreement with Yuhan Corporation for Ryaltris in South Korea

Posted On: 2019-01-10 12:22:58

Glenmark Pharma enters into an Exclusive Licensing Agreement with Yuhan Corporation for Ryaltris in South KoreaGlenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Suisse subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Yuhan Corporation for commercializing its novel nasal spray Ryaltris in South Korea.

The agreement with Yuhan is Glenmark's second regional licensing deal for Ryaltris. In July 2018, Glenmark entered into an exclusive licensing agreement with Seqirus Pty. Ltd. to commercialize Ryaltris in Australia and New Zealand.

Ryaltris [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel, investigational, fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

Under the terms of the agreement, Glenmark will be responsible for manufacturing and supply of the product, while Yuhan will be responsible for regulatory filing and commercialization of Ryaltris in South Korea. Glenmark will receive an upfront payment, regulatory and commercial milestone payments as well as royalties from Yuhan.

"This partnership with Yuhan is in line with our vision to make Ryaltris the first global brand of Glenmark by launching it in several key markets. We are happy to collaborate with Yuhan as it is a strong and reputed player in South Korea and is aligned with Glenmark's objective to provide quality novel products to fulfill unmet needs of patients," said Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals.

In May 2018, Glenmark filed a New Drug Application (NDA) for Ryaltris with the US Food and Drug Administration (US FDA), which is currently under review with the regulator.

Glenmark plans to commercialize Ryaltris in various markets globally. The company will continue to explore commercial partnerships for Ryaltris in markets where it doesn't have direct presence.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.653.5 as compared to the previous close of Rs. 654.8. The total number of shares traded during the day was 14154 in over 390 trades.

The stock hit an intraday high of Rs. 659.8 and intraday low of 649.4. The net turnover during the day was Rs. 9267122.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Vodafone Idea Ltd board to consider fund raising on Jan 23, 2019

Sicagen India Ltd board to consider Q3 results on Feb 13, 2019

Delhi Airport Metro Express updates on arbitration award

SPML Infra Limited board to announce third quarter results on Feb 8, 2019

ITI Limited signs contract with Gujarat Fibre Grid Network Ltd

Swaraj Automotives Ltd board to announce third quarter results on Feb 1, 2019

HDFC Bank announces Q3 FY19 results

JK Agri Genetics Ltd board to announce Q3 results on Jan 30, 2019

K P R Mill Ltd board to consider Q3FY19 results on Jan 28, 2019

Paramount Communications Ltd board to approve 3rd quarter results on Feb 1, 2019

Sutlej Textiles and Industries Ltd board to announce third quarter results on Feb 5, 2019

PSP Projects Ltd receives new work orders worth Rs. 572.17 crores

Sarla Performance Fibers Ltd calls for board meeting on Feb 1, 2019

Bliss GVS Pharma Ltd board to consider Q3FY19 results on Jan 29, 2019

HDFC Bank appoints Mr. Sandeep Parekh as additional independent director

Governance Award for BEML

Munjal Showa Ltd board to approve quarterly results on Feb 4, 2019

IP Rings Ltd board to announce 3rd quarter results on Feb 1, 2019

Dwarikesh Sugar Industries Ltd board to announce Q3 results on Feb 2, 2019

SEBI asks Larsen & Toubro Ltd not to proceed with buyback

HDFC Bank Ltd Q3 net profit rises to Rs. 5585.85 crores

ARO Granite Industries Ltd Q3 PAT soars to Rs. 4.16 crore

Hindustan Oil Exploration Company Ltd posts jump in Q3 PAT to Rs. 34.81 crores

South Indian Bank Ltd Q3 net profit drops to Rs. 83.85 crores

Nava Bharat Ventures Ltd board to announce Q3 results on Feb 7, 2019

Freshtrop Fruits Ltd board to approve 3rd quarter results on Jan 29, 2019

Gujarat Intrux Ltd board to approve quarterly results on Jan 29, 2019

Maithan Alloys Ltd board to announce Q3 results on Jan 28, 2019

Sri Ramakrishna Mills Coimbatore Ltd calls for board meeting on Feb 13, 2019

PVR Cinemas and BookMyShow celebrate the second successful year of VKAAO

SPML Infra Ltd's Chairman received Economic Times Most Promising Business Leaders of Asia 2018 Award

DCM Shriram Industries Ltd board to approve third quarter results on Feb 2, 2019

Machino Plastics Ltd calls for board meeting on Jan 30, 2019

Honda SIEL Power Products Ltd board to announce 3rd quarter results on Feb 6, 2019

Precision Camshafts Ltd board to consider Q3 results on Feb 7, 2019

Vascon Engineers Ltd to raise Rs. 110 crores through NCD issue

Healthcare Global Enterprises Limited calls for board meeting on Feb 7, 2019

Welspun Enterprises Ltd board to consider third quarter result son Jan 29, 2019

RBI approves appointment of V Vaidyanathan as MD & CEO of IDFC First Bank Ltd

International Combustion India Ltd calls for board meeting on Feb 8, 2019

Gujarat Hotels Ltd board to approve third quarter results on Jan 30, 2019

Thangamayil Jewellery Ltd board to announce Q3FY19 results on Feb 8, 2019

Vesuvius India Ltd board to consider Q4, CY18 results on Feb 28, 2019

Rossell India Ltd board to announce 3rd quarter results on Feb 5, 2019

Entertainment Network India Ltd board to approve third quarter results on Feb 6, 2019

CEAT Ltd board to consider Q3 results on Jan 28, 2019

Minda Industries Ltd issues CP of Rs. 30 crore

Zee Learn Limited continues strong growth momentum in Q3 FY19

ICICI Lombard General Insurance Company Ltd announces Q3 results for FY2018-19

SBI Life Insurance Company Ltd announces Q3FY19 results







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019